Q3 EPS Estimates for Fortress Biotech Lifted by Roth Capital

Key Points

• Roth Capital has raised its Q3 2025 earnings per share estimate for Fortress Biotech to ($0.21), up from a previous estimate of ($0.24), with full-year earnings expectations for 2025 set at ($1.30) EPS.
• Despite these revised estimates, Fortress Biotech's stock has recently traded down by 6.4% and opened at $2.05, with a market capitalization of approximately $60.99 million.
• Fortress Biotech's recent quarterly results showed earnings of ($0.46) per share, missing consensus estimates by $0.15, although the company reported revenue of $16.41 million, exceeding analyst projections.

Fortress Biotech, Inc. (NASDAQ:FBIO - Free Report) - Research analysts at Roth Capital raised their Q3 2025 earnings per share estimates for Fortress Biotech in a note issued to investors on Monday, August 18th. Roth Capital analyst J. Wittes now forecasts that the biopharmaceutical company will post earnings per share of ($0.21) for the quarter, up from their prior estimate of ($0.24). The consensus estimate for Fortress Biotech's current full-year earnings is ($3.28) per share. Roth Capital also issued estimates for Fortress Biotech's Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($1.30) EPS and FY2026 earnings at ($0.40) EPS.

Fortress Biotech (NASDAQ:FBIO - Get Free Report) last posted its quarterly earnings results on Thursday, August 14th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.15). The company had revenue of $16.41 million during the quarter, compared to the consensus estimate of $14.53 million. Fortress Biotech had a negative net margin of 24.84% and a negative return on equity of 301.81%.

Separately, HC Wainwright decreased their price target on Fortress Biotech from $26.00 to $17.00 and set a "buy" rating for the company in a research note on Thursday, August 21st. Two research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $16.50.

Fortress Biotech Stock Up 3.7%

FBIO stock traded up $0.09 during mid-day trading on Thursday, reaching $2.38. The company had a trading volume of 394,923 shares, compared to its average volume of 275,924. The company has a debt-to-equity ratio of 1.34, a current ratio of 1.92 and a quick ratio of 1.70. The stock has a 50 day simple moving average of $1.93 and a two-hundred day simple moving average of $1.77. The company has a market capitalization of $70.66 million, a price-to-earnings ratio of -2.26 and a beta of 1.76. Fortress Biotech has a 52 week low of $1.33 and a 52 week high of $2.42.

Hedge Funds Weigh In On Fortress Biotech

A number of institutional investors and hedge funds have recently bought and sold shares of the company. 180 Wealth Advisors LLC increased its holdings in Fortress Biotech by 6.4% in the 2nd quarter. 180 Wealth Advisors LLC now owns 93,050 shares of the biopharmaceutical company's stock worth $173,000 after purchasing an additional 5,600 shares in the last quarter. HB Wealth Management LLC increased its holdings in Fortress Biotech by 6.1% in the 1st quarter. HB Wealth Management LLC now owns 113,350 shares of the biopharmaceutical company's stock worth $177,000 after purchasing an additional 6,500 shares in the last quarter. PFG Investments LLC increased its holdings in Fortress Biotech by 28.4% in the 1st quarter. PFG Investments LLC now owns 45,259 shares of the biopharmaceutical company's stock worth $71,000 after purchasing an additional 10,000 shares in the last quarter. Wolverine Trading LLC acquired a new position in Fortress Biotech in the 4th quarter worth about $26,000. Finally, PVG Asset Management Corp increased its holdings in Fortress Biotech by 3.3% in the 4th quarter. PVG Asset Management Corp now owns 386,295 shares of the biopharmaceutical company's stock worth $782,000 after purchasing an additional 12,505 shares in the last quarter. Institutional investors and hedge funds own 96.51% of the company's stock.

About Fortress Biotech

Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.